索拉非尼联合恩替卡韦治疗乙型肝炎相关性肝癌的不良反应和护理

Adverse reactions of sorafenib combined to entecavir treatment of hepatitis B-related liver cancer and nursing care of it

[目的]分析索拉非尼联合恩替卡韦治疗乙型肝炎相关性肝癌的不良反应,总结护理措施。[方法]对我院经治的26例索拉非尼联合恩替卡韦治疗的乙型肝炎相关性肝癌病人进行临床护理,观察两药联合服用期间出现的不良反应,并予以相应护理措施。[结果]26例病人中,1例病人服药3周后出现Ⅲ度皮肤不良反应而停用索拉非尼,余均可耐受。两药联合的主要不良反应为皮疹、手足综合征、口腔溃疡。[结论]索拉非尼联合恩替卡韦治疗乙型肝炎相关性肝癌的主要不良反应是皮疹和手足综合征,两药联合毒性并未增加,索拉非尼不良反应明显,予以专科护理和积极治疗有助于减轻不良反应。

Obj ective：To retrospectively analyze the adverse reactions and nursing measures of sorafenib plus entecavir treating hepatitis B related liver cancer and summarize the nursing experience.Methods：A total of 26 cases of HBV related liver cancer patients who were treated with sorafenib and entecavir in our hospital received clinical care,and the adverse reactions were observed and appropriate care measures were given.The main adverse reactions of two drug com-bination included rash,hand foot syndrome and mouth ulcers.Con-clusion：The main adverse reactions of sorafenib combined with ente-cavir treatment of hepatitis B related liver cancer were rash and hand foot syndrome,the two-drug combination did not increase toxicity,sorafenib has significantly adverse reactions,and special care and aggressive treatment can help alleviate adverse reactions.